NewTimeSpace News: On 28 August 2026, Frontera Therapeutics filed a listing application with HKEX; incorporated in 2019, the Company is a clinical-stage gene therapy company focused on ophthalmology and cardiovascular diseases, with a pipeline of six in-house developed rAAV gene therapy candidates, including core products FT-002 (XLRP) and FT-003 (nAMD and DME) and key product FT-001 (RPE65-related IRD); its patent portfolio comprises one Japanese patent and 29 patent applications, with US applications for FT-002 and FT-003 receiving notices of allowance in May and June 2026 respectively.
NewTimeSpace News: On 28 August 2026, Betta Pharmaceuticals Co., Ltd. filed a listing application with HKEX; the Company is a biopharmaceutical company operating across the full industry chain at the commercialization stage, profitable for many consecutive years since its first product launch in 2011; its commercialized products icotinib (Kaima'na, EGFR TKI), ensartinib (Beima'na, ALK TKI) and vorolanib (Fumeina, VEGFR/PDGFR inhibitor) are each the first domestic drug of their class approved in China or entering the global market; the Company has a pipeline of over ten clinical programs covering EGFR, ALK and other targets, also exploring breast cancer, renal cancer, hematological diseases and ophthalmology.
NewTimeSpace News: On 28 August 2026, Hangzhou Tangji Medical Technology Co., Ltd. filed a listing application with HKEX; incorporated in 2016, the Company focuses on the treatment and comprehensive management of metabolic diseases, with core product GBS being China's first medical device approved for the endoscopic treatment of obesity, and is expanding to lower-BMI indications, along with 13 pipeline products; according to Frost & Sullivan, China's obese population reached 233.7 million in 2025 and is expected to reach 329.8 million by 2034, and the China EBMT device market is projected to grow at a CAGR of 111.1% from RMB 32 million in 2025 to RMB 1,352 million in 2030.
NewTimeSpace News: On 28 August 2026, Nanjing Novlead Biotechnology Co., Ltd. re-filed its listing application with HKEX; incorporated in 2018, the Company focuses on inhaled nitric oxide (iNO) therapy, with five approved products (including core product iNOwill, approved by the NMPA in 2022 and CE-certified in 2025) and five candidates in development covering critical care, ward, outpatient and home scenarios; its R&D team of 47 employees represents about 27.5% of total headcount, with H1 2026 R&D expenses of approximately RMB 20.3 million; production facilities are located in Yangzhou, Jiangsu and Fangchenggang, Guangxi.
NewTimeSpace News: On 28 August 2026, Zhejiang Chint Electrics Co., Ltd. filed a listing application with HKEX, with CICC, Huatai International and Guotai Junan International as joint sponsors; the Company is a globally leading power and integrated energy solutions provider with two segments — smart electrical products and green energy solutions; as of 30 June 2026 it operates six production bases and nearly 400 distributors in China covering 265 prefecture-level cities, serving over 50 countries and regions overseas; the Company ranks fifth globally and second in China in low-voltage electrical products (largest in China), and ranks first globally in residential PV with cumulative installations of 58.0 GW (12.8% market share).
NewTimeSpace News: On 28 August 2026, Shenzhen Capchem Technology Co., Ltd. filed an updated prospectus with HKEX, with CITIC Securities and CICC as joint sponsors; the Company is a China-headquartered provider of electronic chemicals and functional materials with three business segments — battery chemicals, organic fluorochemicals and electronic information chemicals — serving industries including NEV, energy storage, consumer electronics, AI and digital infrastructure and semiconductor manufacturing, with 13 production bases; founded in 2002 with its predecessor dating to 1996, the Company primarily adopts a direct sales model, with direct sales accounting for approximately 90% of revenue in recent periods.
NewTimeSpace News: On 28 August 2026, VivaVision Biotech (Zhejiang) Co., Ltd. filed a listing application with HKEX, with CICC as sole sponsor; founded in 2016, the Company is a clinical-stage biotech company focused on ophthalmology, with two core products — VVN461 (high dose), a JAK1/TYK2 dual-target inhibitor for non-infectious anterior uveitis, and VVN001, a second-generation LFA-1 antagonist for moderate-to-severe dry eye disease — both in Phase III trials in China, plus three other clinical-stage candidates; the Company has no approved drugs and its commercialization will rely primarily on collaboration with well-known pharmaceutical companies.
NewTimeSpace News: On 31 August 2026, Excelland Robotics (03231.HK) announced a global offering of 45,000,000 H shares at an offer price range of HKD 14.45-19.55 per share, with 200 shares per board lot and an entry fee of approximately HKD 3,949.44; the Hong Kong public offering runs from 9:00 a.m. on 31 August to 12:00 noon on 4 September, with expected pricing on 7 September, results by 8 September and listing on 9 September; based on a mid-point offer price of HKD 17.00, 2 cornerstone investors (SensePower and CYGG) have subscribed for approximately 1,389,200 shares in aggregate, representing approximately 3.09% of the offer shares and approximately 0.33% of the issued share capital; the Company is applying for a listing under Chapter 18C of the Listing Rules.
NewTimeSpace News: On 31 August 2026, Longsys (09976.HK) announced a global offering of 26,077,800 H shares at a maximum offer price of HKD 240.60 per share, with 50 shares per board lot and an entry fee of approximately HKD 12,151.32; the Hong Kong public offering runs from 9:00 a.m. on 31 August to 12:00 noon on 3 September, with expected pricing on 4 September, the final offer price and application results to be announced by 7 September, and the H shares expected to commence trading on 8 September; a total of 15 cornerstone investors have been introduced with an aggregate subscription of approximately 4,926,050 shares, representing approximately 18.89% of the total offer shares; the stabilising manager is CLSA Limited, with the stabilising period ending on 3 October 2026.
NewTimeSpace News: The CSRC has issued a filing notice for overseas issuance and listing to Red Avenue New Materials Group Co., Ltd., which plans to issue no more than 78,724,900 overseas listed ordinary shares for listing on the Stock Exchange of Hong Kong; the Company is required to report within 15 working days after the completion of the issuance and listing.
NewTimeSpace News: The CSRC has issued a filing notice for overseas issuance and listing to Suzhou Leadsynbio Technology Co., Ltd., which plans to issue no more than 18,271,600 overseas listed ordinary shares for listing on the Stock Exchange of Hong Kong, with 27 shareholders converting an aggregate of 47,665,277 domestic unlisted shares into overseas listed shares (full circulation); the Company is required to report within 15 working days after the completion of the issuance and listing.
NewTimeSpace News: On 28 August 2026, NEBULA ELECTRONICS (300648.SZ) announced that its board had approved a plan to issue H shares and list on the Main Board of the Hong Kong Stock Exchange, aiming to advance its internationalization strategy; the issuance and listing are subject to shareholders' meeting deliberation and approvals or filings from the CSRC, the SFC and the Stock Exchange, with no details finalized and significant uncertainty as to final implementation.
NewTimeSpace News: Medcaptain Medical Technology Co., Ltd.(02041.HK) officially launched its H-share IPO on 28 August 2026. The offer price is set at HK$15.420 per share, with 100 shares per board lot and an entry cost of approximately HK$1,557.55. The company is expected to be listed on the Main Board of the Hong Kong Stock Exchange on 7 September 2026. A total of 38.9106 million shares will be offered globally, including 10% for Hong Kong public offer and 90% for international offer. The total fundraising amount is about HK$600 million, with net proceeds of roughly HK$496 million. The offer ratio stands at approximately 7.22%, and the total share capital after issuance will be around 539 million shares.
NewTimeSpace News: On 27 August 2026, Dizal Pharmaceutical Co., Ltd. filed a listing application with HKEX, with Goldman Sachs and Huatai International as joint sponsors; its core product sunvozertinib is the world's first small-molecule EGFR-TKI approved for EGFR exon20ins-mutant lung cancer (approved in the US and included in the NRDL), and golidocitinib is the world's only JAK1 inhibitor approved for r/r PTCL; on 14 July 2026, the Company entered into a global exclusive license agreement with AstraZeneca for sunvozertinib, with an upfront payment of USD 600.0 million (the largest upfront in a single-asset license-out for a Chinese small-molecule drug to date), plus development milestone payments of up to USD 400.0 million and sales milestone payments of up to USD 500.0 million.
NewTimeSpace News: On 28 August 2026, Medcaptain Medical Technology Co., Ltd. (stock code: 02041) commenced its global offering of 38,910,600 H shares, comprising 3,891,100 H shares under the......
NewTimeSpace News: On 27 August 2026, Transwarp Technology (Shanghai) Co., Ltd. passed the HKEX listing hearing, with Haitong International as sole sponsor; by revenue, the Company is China's fifth-largest AI infrastructure software provider (2.7% market share in 2025) and the largest independent service provider, and the first database enterprise globally to pass TPC-DS audit; its products cover big data platforms, distributed databases, AI platforms and knowledge platforms, serving over 1,800 customers including 105 Fortune China 500 enterprises, with repeat purchase revenue from existing customers averaging over 70% of total revenue.
